HPB-092 for relapsed or refractory AML
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a new drug, HPB-092, in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if it can help when other treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your AML must have returned after treatment or not responded to treatment.
- You must be in generally good health with a life expectancy of at least 12 weeks.
- Your kidney, liver, and heart function must be within certain limits.
- You must not be pregnant or breastfeeding, and must use effective birth control if needed.
- You must not have other serious medical conditions or infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This phase 1 trial tests a new drug called PLM-102 for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard treatment. The goal is to find the best dose and see if it can help control the leukemia.
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
Hear when a new Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.